<SEC-DOCUMENT>0001193125-25-132299.txt : 20250530
<SEC-HEADER>0001193125-25-132299.hdr.sgml : 20250530
<ACCEPTANCE-DATETIME>20250530171406
ACCESSION NUMBER:		0001193125-25-132299
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250530
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250530
DATE AS OF CHANGE:		20250530

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zymeworks Inc.
		CENTRAL INDEX KEY:			0001937653
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				883099146
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41535
		FILM NUMBER:		251012200

	BUSINESS ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709
		BUSINESS PHONE:		302-274-8744

	MAIL ADDRESS:	
		STREET 1:		108 PATRIOT DRIVE, SUITE A
		CITY:			MIDDLETOWN
		STATE:			DE
		ZIP:			19709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zymeworks Delaware Inc.
		DATE OF NAME CHANGE:	20220712
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d18018d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:zyme="http://www.zymeworks.com/20250530" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-283">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-05-30_to_2025-05-30">0001937653</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="zyme-20250530.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-05-30_to_2025-05-30"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001937653</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-05-30</xbrli:startDate> <xbrli:endDate>2025-05-30</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-294">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt:datemonthdayyearen" id="ixv-295">May 30, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-296">Zymeworks Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:stateprovnameen" id="ixv-297">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-298">001-41535</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-299">88-3099146</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or other jurisdiction<br/>of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-300">108 Patriot Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-301">Suite A</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-302">Middletown</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:stateprovnameen" id="ixv-303">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-304">19709</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-305">(302)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-306">274-8744</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:boolballotbox" id="ixv-307">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:boolballotbox" id="ixv-308">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:boolballotbox" id="ixv-309">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:boolballotbox" id="ixv-310">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-311">Common Stock, par value $0.00001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-312">ZYME</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:exchnameen" id="ixv-313">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-05-30_to_2025-05-30" format="ixt-sec:boolballotbox" id="ixv-314">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;30, 2025, Zymeworks Inc. (&#8220;Company&#8221;) issued a press release announcing that the National Medical Products Administration in China (the &#8220;NMPA&#8221;) has approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive (&#8220;HER2+&#8221;) biliary tract cancer (&#8220;BTC&#8221;). A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information provided under this Item 7.01 (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks BC Inc. (&#8220;Zymeworks&#8221;), a subsidiary of the Company, is a party to a License and Collaboration Agreement (as amended, the &#8220;License and Collaboration Agreement&#8221;) with BeOne Medicines Ltd. (&#8220;BeOne&#8221;) (formerly BeiGene, Ltd.), granting BeOne an exclusive license for the research, development, and commercialization of zanidatamab, Zymeworks&#8217; proprietary bispecific HER2 antibody, in Asia (excluding Japan, but including the People&#8217;s Republic of China, South Korea and other countries), Australia, and New Zealand. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As announced on May 30, 2025, the NMPA granted conditional approval of zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive (HER2+) BTC. The NMPA conditional approval was based on results of the <span style="white-space:nowrap"><span style="white-space:nowrap">HERIZON-BTC-01</span></span> clinical study, which demonstrated overall survival benefit for patients treated with zanidatamab. Continued approval of this indication will depend on the verification of clinical benefit in the patient population through ongoing confirmatory trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the License and Collaboration Agreement, Zymeworks has received $61&#160;million in upfront and milestone payments, as well as certain <span style="white-space:nowrap">co-development</span> funding for zanidatamab clinical studies. Zymeworks is entitled to receive a $20&#160;million milestone payment in connection with the NMPA approval of zanidatamab, and is eligible to receive up to $144&#160;million in additional development and commercial milestones. Zymeworks is also eligible to receive tiered royalties of up to 19.5% of net sales in BeOne Medicine&#8217;s territories, increasing to up to 20% when cumulative amounts foregone as a result of a royalty reduction of 0.5% reaches a cap in the low double-digit millions of dollars. For additional information regarding the License and Collaboration Agreement, please refer to the Current Reports on Form <span style="white-space:nowrap">8-K,</span> filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) by Zymeworks on <a href="http://www.sec.gov/Archives/edgar/data/1403752/000119312518334441/d596335d8k.htm">November&#160;27, 2018</a> and <a href="http://www.sec.gov/Archives/edgar/data/1403752/000134100418000648/form8-ka.htm">December&#160;6, 2018</a> and the Current Report on Form <span style="white-space:nowrap">8-K,</span> filed with the SEC by the Company on <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001937653/000119312523239601/d549533d8k.htm">September&#160;21, 2023</a>, as well as copies of the License and Collaboration Agreement and amendments, incorporated by reference as exhibits to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K,</span> filed with the SEC on <a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1937653/000193765325000014/zyme-20241231.htm">March&#160;5, 2025</a>. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:7%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit&#160;No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d18018dex991.htm">Press Release, dated May&#160;30, 2025</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded as Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:5%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:44%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">ZYMEWORKS INC.</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="3">(Registrant)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: May&#160;30, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Leone Patterson</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name:</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title:</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leone Patterson</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Business Officer and Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d18018dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g18018g0530222705446.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated,
Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract
cancer in China; conditional approval based on the results of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HERIZON-BTC-01</FONT></FONT> clinical study</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>$20</I><I></I><I>&nbsp;million milestone payment to be received from BeOne Medicines; Zymeworks remains
eligible to receive up to $144</I><I></I><I>&nbsp;million in additional development and commercial milestones </I> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Vancouver, British
Columbia (May 30, 2025)</B> &#150; Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> diseases, including cancer, inflammation, and autoimmune disease, today announced that the National Medical Products Administration (NMPA) in China has approved zanidatamab for the
treatment of patients with previously treated, unresectable or metastatic HER2-positive (HER2+) biliary tract cancer (BTC). The conditional approval marks the first and only<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> dual HER2-targeted
bispecific antibody approved for HER2-high expression (IHC3+) BTC in China. Zymeworks&#146; collaboration partner, BeOne Medicines Ltd. (formerly BeiGene, Ltd), obtained the conditional approval under the terms of its Asia Pacific license and
collaboration agreement with Zymeworks. Continued approval of this indication will depend on the verification of clinical benefit in the patient population through ongoing confirmatory trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Zanidatamab&#146;s conditional approval in&nbsp;China&nbsp;is a meaningful advancement for patients living with HER2-positive BTC, a population with
historically high unmet need and poor prognoses,&#148; said&nbsp;Kenneth Galbraith, Chair and Chief Executive Officer of&nbsp;Zymeworks. &#147;This milestone affirms the strength of zanidatamab&#146;s clinical potential and reflects our continued
focus on translating innovation into real impact for patients around the globe. We are deeply grateful to our partners at BeOne Medicines, and to the patients, families, and clinical teams whose contributions have made this milestone a reality. As
Zymeworks continues to advance our broader development programs and R&amp;D pipeline, we remain committed to realizing zanidatamab&#146;s potential to transform the standard of care across HER2-expressing cancers.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of its agreement with BeOne Medicines,&nbsp;Zymeworks&nbsp;has received $61&nbsp;million in upfront&nbsp;and milestone payments, as well as
certain <FONT STYLE="white-space:nowrap">co-development</FONT> funding for zanidatamab clinical studies. Zymeworks is entitled to receive a $20 million&nbsp;milestone payment in connection with the NMPA approval of zanidatamab, and is eligible to
receive up to&nbsp;$144 million&nbsp;in additional development and </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">According to publicly available information, as of the approval announcement on May&nbsp;29, 2025, zanidatamab
is the only HER2-targeting bispecific antibody approved by the National Medical Products Administration (NMPA) for HER2-high-expression biliary tract cancer (BTC). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercial milestones. Zymeworks is also eligible to receive tiered royalties of up to 19.5% of net sales in BeOne Medicine&#146;s territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab was <U>approved by the U.S. Food and Drug Administration (FDA)</U> in November 2024 for the treatment of adults with previously treated,
unresectable or metastatic HER2+ (IHC 3+) BTC. In April 2025, Zymeworks&#146; partner, Jazz Pharmaceuticals, announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) <U>adopted a positive opinion
recommending the approval of zanidatamab</U> for the treatment of advanced HER2+ BTC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Biliary Tract Cancer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biliary tract cancers (BTC), including gallbladder cancer and intrahepatic and extrahepatic cholangiocarcinoma, account for approximately 3% of all digestive
system tumors and are often associated with a poor prognosis<SUP STYLE="font-size:75%; vertical-align:top">2</SUP><SUP STYLE="font-size:75%; vertical-align:top">,</SUP><SUP STYLE="font-size:75%; vertical-align:top">3</SUP><SUP
STYLE="font-size:75%; vertical-align:top">,</SUP><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>. Approximately <FONT STYLE="white-space:nowrap">11%-25.2%</FONT> of patients with BTC are HER2-positive<SUP
STYLE="font-size:75%; vertical-align:top">5</SUP><SUP STYLE="font-size:75%; vertical-align:top">,</SUP><SUP STYLE="font-size:75%; vertical-align:top">6</SUP><SUP STYLE="font-size:75%; vertical-align:top">,</SUP><SUP
STYLE="font-size:75%; vertical-align:top">7</SUP>. The human epidermal growth factor receptor 2 (HER2) is a well-validated target for antitumor therapy in other cancers<SUP STYLE="font-size:75%; vertical-align:top">3,</SUP><SUP
STYLE="font-size:75%; vertical-align:top">8</SUP>. The incidence rate of BTC is on the rise globally, in particular in Asian countries and regions.<SUP STYLE="font-size:75%; vertical-align:top">9</SUP> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About zanidatamab </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zanidatamab is a dual HER2-targeted
bispecific antibody that simultaneously binds extracellular domains 2 and 4 on separate HER2 monomers (binding in trans). Binding of zanidatamab with HER2 results in internalization leading to a reduction of the receptor on the cell surface.
Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and tumor cell death.<SUP
STYLE="font-size:75%; vertical-align:top">10</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zymeworks Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional
biotherapeutics. Zymeworks&#146; mission is to make a meaningful difference in the lives of people impacted by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> conditions such as cancer,
inflammation, and autoimmune disease. The Company&#146;s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated
antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company&#146;s proprietary Azymetric<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> technology.
Zymeworks has entered into separate agreements with BeOne Medicines Ltd. </P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</DIV>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chinese Society of Clinical Oncology (CSCO). Diagnosis and Treatment Guidelines for Biliary Malignant Tumors
(2024). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vogel A, Bridgewater J, Edeline J, et al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis,
treatment, and <FONT STYLE="white-space:nowrap">follow-up.</FONT> Ann Oncol. <FONT STYLE="white-space:nowrap">2023;34(2):127-40.</FONT> doi:10.1016/j.annonc.2022.10.506. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">4</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chakrabarti, S., Kamgar.<U>doi.org/10.3390/cancers12082039</U>. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Choong-kun</FONT> Lee, et al. 2025 ASCO GI Abstr. #629. </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Hiraoka N, et al. Hum Pathol. 2020 <FONT STYLE="white-space:nowrap">Nov:105:9-19.</FONT> </P></TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">7</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vivaldi C, et al. Oncologist. 2020 <FONT STYLE="white-space:nowrap">Oct;25(10):886-893.</FONT>
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">8</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Meric-Bernstam, F., Beeram, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally
advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. The Lancet Oncology. 2022; doi: <FONT STYLE="white-space:nowrap">10.1016/S1470-2045(22)00621-0.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">9</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Chinese Society of Clinical Oncology (CSCO) Biliary Tumor Expert Committee Expert consensus on precise
detection and molecular diagnosis of biliary malignant tumors [J]. Journal of Clinical Oncology, 2024, 29 (8): <FONT STYLE="white-space:nowrap">797-804.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">10</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Weisser NE, Sanches M, Escobar-Cabrera E et al. An anti-HER2 biparatopic antibody that induces unique HER2
clustering and complement-dependent cytotoxicity. Nature Communications. 2023 Mar 13;14(1):1394. doi: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1038/s41467-023-37029-3.</FONT></FONT></FONT>
</P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted
accelerated approval and China&#146;s NMPA granted conditional approval for zanidatamab to treat adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer. Zanidatamab is the first and only dual
HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. and China. Zanidatamab is currently under regulatory review in the EU for second-line BTC and is being evaluated in multiple global clinical trials as a potential <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its
expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug
application for ZW251 planned for <FONT STYLE="white-space:nowrap">mid-2025.</FONT> In addition to Zymeworks&#146; pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical
companies. For information about Zymeworks, visit <U>www.zymeworks.com</U> and follow <U>@ZymeworksInc</U> on X. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding
Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release includes &#147;forward-looking statements&#148; or information within the meaning of the applicable
securities legislation, including Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to,
statements that relate to the efficacy and safety of zanidatamab; ongoing clinical studies and regulatory reviews; the anticipated benefits of the collaboration agreement with BeOne Medicines, including Zymeworks&#146; ability to receive any future
milestone payments and royalties thereunder; the potential addressable market of zanidatamab; the timing of and results of interactions with regulators; Zymeworks&#146; clinical development of its product candidates and enrollment in its clinical
trials; the timing and status of ongoing and future studies and the related data; expectations regarding future regulatory filings and approvals and the timing thereof; potential safety profile and therapeutic effects of zanidatamab; the commercial
potential of technology platforms and product candidates; Zymeworks&#146; ability to satisfy potential regulatory and commercial milestones with existing and future partners and anticipated continued receipt of revenue from existing and future
partners. When used herein, words such as &#147;plan&#148;, &#147;believe&#148;, &#147;expect&#148;, &#147;may&#148;, &#147;anticipate&#148;, &#147;potential&#148;, &#147;will&#148;, &#147;continues&#148;, and similar expressions are intended to
identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks&#146; current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently
uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including,
without limitation: clinical trials, including any required confirmatory trials, may not demonstrate safety and efficacy of any of Zymeworks&#146; or its collaborators&#146; product candidates; any of Zymeworks&#146; or its partners&#146; product
candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; conditional regulatory approval may be withdrawn or revoked if any of Zymeworks&#146; or its
partners&#146; product candidates fail to satisfy the requirements of any such conditional regulatory approvals; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws
and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty and new policies implemented under the current administration, including executive orders, changes in the
leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks&#146; business, research and clinical
development plans and timelines and results of operations, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks&#146; behalf; clinical trials and any future clinical trials may not demonstrate safety
and efficacy of any of Zymeworks&#146; or its collaborators&#146; product candidates;&nbsp;inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under &#147;Risk Factors&#148; in Zymeworks&#146;
quarterly and annual reports filed with the&nbsp;Securities and Exchange Commission&nbsp;(copies of which may be obtained at&nbsp;<U>www.sec.gov</U>&nbsp;and&nbsp;<U>www.sedarplus.ca</U>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not
place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no
obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor inquiries: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shrinal Inamdar </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT
STYLE="white-space:nowrap">678-1388</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@zymeworks.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media inquiries: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diana Papove </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(604) <FONT
STYLE="white-space:nowrap">678-1388</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@zymeworks.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>zyme-20250530.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 5/31/2025 1:10:18 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:zyme="http://www.zymeworks.com/20250530"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.zymeworks.com/20250530"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20250530_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="zyme-20250530_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>zyme-20250530_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 5/31/2025 1:10:18 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>zyme-20250530_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 5/31/2025 1:10:18 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="zyme-20250530.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g18018g0530222705446.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g18018g0530222705446.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I .D# 2(  A$! Q$!_\0
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MJ@UMIH&D1W7VE--M5FSG>(QFM&OKL5C?;1Y4K&>&P?L9<S=PHHHK@.X****
M"BBB@ HHHH **** "DI:2@!:*8\T46/,D1,]-S 4S[7;?\_$7_?8J7**W8$U
M%1+<P,<+-&3C/#"E2XAD;:DT;'T# T<T>X$E%(2%!+$ #J34:W$#G"S1L>N
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M.V*FG\/Z>D>_P]XCF34%(,:O>[E;U!%16^K^ 9K=)+^RMK>[*CS8FMF&UN_
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@ 4444 %%%% !1110 4444 %%%% !1110 4E+24 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001937653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 30,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Zymeworks Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-3099146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">108 Patriot Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Middletown<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">274-8744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ZYME<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d18018d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d18018d8k.htm">d18018d8k.htm</File>
    <File>zyme-20250530.xsd</File>
    <File>zyme-20250530_lab.xml</File>
    <File>zyme-20250530_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d18018d8k.htm": {
   "nsprefix": "zyme",
   "nsuri": "http://www.zymeworks.com/20250530",
   "dts": {
    "inline": {
     "local": [
      "d18018d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "zyme-20250530.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "zyme-20250530_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "zyme-20250530_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-05-30_to_2025-05-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d18018d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-05-30_to_2025-05-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d18018d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.zymeworks.com//20250530/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-25-132299-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-132299-xbrl.zip
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M5'-*SCF@0^T072CD>;0?'V CK3O!]*84V<_J8L:D;% W=4':M7UB5SXS[A5
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MKL'GHTJMB+-6RW^EIM\SD.=IOT=SW2Y.RE;F!'B,O,V@R^=PMU"(_^7CG]W
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MCK@?S4^D],'^\4$%F8E()TJ,=)RD0H:^,"&PZ&? ,&,MQ7(*L!1#G43*TR.
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ME=9KCX2E/W/@)ESDUA+'H>A%L0Z<#"_&;T7$]JO\_%E<3"1TA,?I!K"RL2Q
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M+AGUR@Z9NP!"QKO+&6I+E3@\*;/4%C$&MG )Q]VCI!.Y6_8X<:Y+\K$E"(S
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M9KMQ[6U7L6Z.V?8@MS?]@6^NFH5#/_\%4$L#!!0    ( ,*)OEIXZ^]!>@8
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M&X:'?+9>RCNNU);^E2OY+IK]XA&UYW]02P,$%     @ PHF^6N8YE]+"!
M02P  !4   !Z>6UE+3(P,C4P-3,P7W!R92YX;6S5FEV/XC84AN]7VO_@IC>M
MU! ",^T.&F9%F9D*=;X$;%OU9F62 UCKV,@V _37]SC@ED"8A=EM%7/!A^/W
M^/5Y'!,[N7R_S#AY!J69%.T@KM4# B*1*1.3=C#7(=4)8P'1AHJ4<BF@':Q
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M  !D,3@P,3AD97@Y.3$N:'1M4$L! A0#%     @ PHF^6JUKF+4_ P  3PL
M !$              ( !6RT  'IY;64M,C R-3 U,S N>'-D4$L! A0#%
M  @ PHF^6GCK[T%Z!@  N48  !4              ( !R3   'IY;64M,C R
M-3 U,S!?;&%B+GAM;%!+ 0(4 Q0    ( ,*)OEKF.9?2P@0  $$L   5
M          "  78W  !Z>6UE+3(P,C4P-3,P7W!R92YX;6Q02P4&      4
,!0 ^ 0  :SP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d18018d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="zyme-20250530.xsd" xlink:type="simple"/>
    <context id="duration_2025-05-30_to_2025-05-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001937653</identifier>
        </entity>
        <period>
            <startDate>2025-05-30</startDate>
            <endDate>2025-05-30</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-283">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-05-30_to_2025-05-30"
      id="Hidden_dei_EntityCentralIndexKey">0001937653</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-294">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-295">2025-05-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-296">Zymeworks Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-297">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-298">001-41535</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-299">88-3099146</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-300">108 Patriot Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-301">Suite A</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-302">Middletown</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-303">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-304">19709</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-305">(302)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-306">274-8744</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-307">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-308">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-309">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-310">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-311">Common Stock, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-312">ZYME</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-313">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-05-30_to_2025-05-30" id="ixv-314">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
